Home > Publications database > Cost effectiveness and health-related quality of life of chemoradiotherapy versus radiation therapy alone in elderly head and neck cancer patients. > print

001     180676
005     20240229145628.0
024 7 _ |a 10.1007/s00066-022-01975-6
|2 doi
024 7 _ |a pmid:35833963
|2 pmid
024 7 _ |a 0179-7158
|2 ISSN
024 7 _ |a 1439-099X
|2 ISSN
024 7 _ |a altmetric:132518458
|2 altmetric
037 _ _ |a DKFZ-2022-01476
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Sprave, Tanja
|0 P:(DE-HGF)0
|b 0
245 _ _ |a Cost effectiveness and health-related quality of life of chemoradiotherapy versus radiation therapy alone in elderly head and neck cancer patients.
260 _ _ |a Heidelberg
|c 2022
|b Springer Medizin
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1674638029_13517
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2022 Nov;198(11):1008-1015 / #LA:E055#
520 _ _ |a Radiotherapy (RT) constitutes a mainstay in the treatment of elderly patients with head and neck cancer (HNC), but use of simultaneous chemoradiotherapy (CRT) remains controversial. We have conducted a prospective analysis based on real-world patient data to examine the health-related quality of life (HRQoL) and cost effectiveness (CE) of CRT vs. RT in elderly HNC patients.Eligible participants ≥ 65 years treated in a large tertiary cancer center between July 2019 and February 2020 who completed the validated EQ-5D-5L questionnaire (health state index [HI] and visual analog scale [VAS]) before and after RT were included. CE referred to direct medical costs, including diagnosis-related group (DRG)-based billings for inpatients and uniform assessment standard (EBM)-based costs for outpatients. The primary endpoint was cost (euros [€]) per quality-adjusted life year (QALY). The incremental cost-effectiveness ratios (ICERs) were calculated. Costs and QALYs were not discounted for short overall survival (OS).Baseline HRQoL was 0.878 (±0.11) in the CRT group and 0.857 (±0.17) in the RT group. Upon completion of therapy, HRQoL amounted to 0.849 (±0.14) in the CRT and 0.850 (±0.13) in the RT group. The mean treatment-related cost in the CRT cohort was €22,180.17 (±8325.26) vs. €18,027.87 (±26,022.48) in the RT group. The corresponding QALYs amounted to 2.62 in the CRT and 1.91 in the RT groups. The ICER was €5848.31.This is the first analysis from the German health care system demonstrating that the addition of chemotherapy to RT for selected elderly HNC patients is cost effective and not associated with a significant HRQoL decline.
536 _ _ |a 315 - Bildgebung und Radioonkologie (POF4-315)
|0 G:(DE-HGF)POF4-315
|c POF4-315
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Chemoradiation
|2 Other
650 _ 7 |a EQ‑5D
|2 Other
650 _ 7 |a Geriatric patients
|2 Other
650 _ 7 |a Head and neck squamous cell carcinoma
|2 Other
650 _ 7 |a Quality-adjusted life year
|2 Other
700 1 _ |a Verma, Vivek
|b 1
700 1 _ |a Fabian, Alexander
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Rühle, Alexander
|0 P:(DE-He78)80e100a16534f5fc67f7436ee67a47f9
|b 3
700 1 _ |a Baltas, Dimos
|0 P:(DE-HGF)0
|b 4
700 1 _ |a Grosu, Anca-Ligia
|0 P:(DE-HGF)0
|b 5
700 1 _ |a Nicolay, Nils
|0 P:(DE-He78)8d52e7ff1ccaac7dbf0232fdcb0168bd
|b 6
|e Last author
773 _ _ |a 10.1007/s00066-022-01975-6
|0 PERI:(DE-600)2003907-4
|n 11
|p 1008-1015
|t Strahlentherapie und Onkologie
|v 198
|y 2022
|x 0179-7158
909 C O |p VDB
|o oai:inrepo02.dkfz.de:180676
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)80e100a16534f5fc67f7436ee67a47f9
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)8d52e7ff1ccaac7dbf0232fdcb0168bd
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-315
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Bildgebung und Radioonkologie
|x 0
914 1 _ |y 2022
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2021-01-26
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-01-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-01-26
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-01-26
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b STRAHLENTHER ONKOL : 2021
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2022-11-11
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2022-11-11
920 2 _ |0 I:(DE-He78)E055-20160331
|k E055
|l E055 KKE Molekulare Radioonkologie
|x 0
920 1 _ |0 I:(DE-He78)FR01-20160331
|k FR01
|l DKTK FR zentral
|x 0
920 1 _ |0 I:(DE-He78)E055-20160331
|k E055
|l E055 KKE Molekulare Radioonkologie
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)FR01-20160331
980 _ _ |a I:(DE-He78)E055-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21